Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sonoma Pharmaceuticals (SNOA) Return on Capital Employed (2016 - 2025)

Sonoma Pharmaceuticals has reported Return on Capital Employed over the past 15 years, most recently at 29.05% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 1570.0% year-over-year to 29.05%; the TTM value through Dec 2025 reached 29.05%, up 1570.0%, while the annual FY2025 figure was 36.66%, 329.0% up from the prior year.
  • Return on Capital Employed for Q4 2025 was 29.05% at Sonoma Pharmaceuticals, up from 31.5% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 27.52% in Q1 2021 and troughed at 61.65% in Q4 2022.
  • A 5-year average of 40.78% and a median of 40.69% in 2023 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: soared 4091bps in 2021 and later crashed -2575bps in 2022.
  • Year by year, Return on Capital Employed stood at 35.89% in 2021, then plummeted by -72bps to 61.65% in 2022, then skyrocketed by 35bps to 40.16% in 2023, then fell by -11bps to 44.75% in 2024, then soared by 35bps to 29.05% in 2025.
  • Business Quant data shows Return on Capital Employed for SNOA at 29.05% in Q4 2025, 31.5% in Q3 2025, and 39.07% in Q2 2025.